Yme Alkema

Kiadis BV is a drug discovery and development company with a focus on oncology and metabolic disorders. Kiadis has developed a proprietary technology platform, BioSelact technology that is used to perform drug discovery screening programs using natural extracts as well as synthetic mixtures and with the key advantage of direct identification and dereplication of the active compounds present in extracts or mixtures. The company is headquartered in Groningen, the Netherlands.

Atugen AG is a biopharmaceutical company. It develops RNAi therapeutics which focus on vivo applications in oncology and liver diseases, exploiting its proprietary oligonucleotide delivery technologies and chemically stabilized siRNA structures. Founded in 1998, the company is headquartered in Berlin, Germany